Lin BioScience Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to eva… Read more
Lin BioScience Inc. (6696) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.000x
Based on the latest financial reports, Lin BioScience Inc. (6696) has a cash flow conversion efficiency ratio of 0.000x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-710.06K) by net assets (NT$5.35 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lin BioScience Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Lin BioScience Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lin BioScience Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lin BioScience Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northwest Healthcare Properties REIT
PINK:NWHUF
|
0.008x |
|
Chambal Fertilizers & Chemicals Limited
NSE:CHAMBLFERT
|
0.035x |
|
TRUSTPILOT GROUP LS -01
F:6VZ
|
N/A |
|
Guangdong CHJ Industry Co Ltd
SHE:002345
|
0.054x |
|
Maanshan Iron & Steel Company Limited
PINK:MAANF
|
0.021x |
|
Core Laboratories NV
NYSE:CLB
|
0.028x |
|
Jinzi Ham Co Ltd
SHE:002515
|
-0.006x |
|
Nagarro SE
PINK:NGRRF
|
0.295x |
Annual Cash Flow Conversion Efficiency for Lin BioScience Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Lin BioScience Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.35 Billion | NT$-1.02 Billion | -0.190x | +35.54% |
| 2023-12-31 | NT$3.43 Billion | NT$-1.01 Billion | -0.295x | -42.04% |
| 2022-12-31 | NT$1.74 Billion | NT$-361.01 Million | -0.208x | +67.50% |
| 2021-12-31 | NT$452.98 Million | NT$-289.83 Million | -0.640x | -222.39% |
| 2020-12-31 | NT$909.99 Million | NT$-180.61 Million | -0.198x | +86.49% |
| 2019-12-31 | NT$142.75 Million | NT$-209.66 Million | -1.469x | -- |